Loading stock data…
TECH
$54.41+1.76 (+3.34%)
Market ClosedLast close Jun 9
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bio-Techne Corporation in the Healthcare sector is trading at $54.41. Wall Street consensus targets $61.42 (12 analysts), implying a +12.9% move over the next 12 months. The stock is currently 25% below its 52-week high of $72.16, remaining 5.1% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 79 is overbought against a weak tape. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +12.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 79 against a weak tape — risk of pullback
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$54.41
Potential Downside
0%
Whystock Fair Value$54.41
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Buy
Mean target$61.42+12.9%
Range$49.00 – $75.00
Fundamentals
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.44%
ROE
Average efficiency. Growth may require heavy reinvestment.
5.25%
Volume
Today's trading volume
3.53M
Recent News
New Bispecific Antibody Characterization Workflow Might Change The Case For Investing In Bio-Techne (TECH)
Earlier this week, Bio-Techne and Refeyn announced a first-of-its-kind integrated workflow that links Bio-Techne’s MauriceFlex™ icIEF fractionation system with Refeyn’s TwoMP mass photometry platform, enabling four-hour, single-molecule characterization of charge and size variants in bispecific antibodies and biosimilars. This workflow directly connects charge heterogeneity with molecular weight and aggregation using nanogram-level samples, potentially streamlining biotherapeutic...
3 Reasons TECH is Risky and 1 Stock to Buy Instead
Over the past six months, Bio-Techne’s stock price fell to $51.95. Shareholders have lost 13.8% of their capital, which is disappointing considering the S&P 500 has climbed by 10.7%. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
Why Is Techne (TECH) Up 4.5% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Are Wall Street Analysts Bullish on Bio-Techne Stock?
While Bio-Techne has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.